SSSS vs. HQL, TYG, KTF, SOR, MCI, PPT, MIY, MHN, PMO, and ASG
Should you be buying SuRo Capital stock or one of its competitors? The main competitors of SuRo Capital include Abrdn Life Sciences Investors (HQL), Tortoise Energy Infrastructure (TYG), DWS Municipal Income Trust (KTF), Source Capital (SOR), Barings Corporate Investors (MCI), Putnam Premier Income Trust (PPT), BlackRock MuniYield Michigan Quality Fund (MIY), BlackRock MuniHoldings New York Quality Fund (MHN), Putnam Municipal Opportunities Trust (PMO), and Liberty All-Star Growth Fund (ASG). These companies are all part of the "investment offices, not elsewhere classified" industry.
SuRo Capital (NASDAQ:SSSS) and Abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.
13.0% of SuRo Capital shares are held by institutional investors. Comparatively, 32.2% of Abrdn Life Sciences Investors shares are held by institutional investors. 6.0% of SuRo Capital shares are held by company insiders. Comparatively, 10.1% of Abrdn Life Sciences Investors shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Abrdn Life Sciences Investors has a net margin of 0.00% compared to SuRo Capital's net margin of -316.66%. Abrdn Life Sciences Investors' return on equity of 0.00% beat SuRo Capital's return on equity.
SuRo Capital currently has a consensus target price of $6.00, indicating a potential upside of 47.78%. Given SuRo Capital's higher probable upside, analysts clearly believe SuRo Capital is more favorable than Abrdn Life Sciences Investors.
SuRo Capital has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Abrdn Life Sciences Investors has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Abrdn Life Sciences Investors received 50 more outperform votes than SuRo Capital when rated by MarketBeat users. However, 71.43% of users gave SuRo Capital an outperform vote while only 68.35% of users gave Abrdn Life Sciences Investors an outperform vote.
SuRo Capital has higher revenue and earnings than Abrdn Life Sciences Investors.
In the previous week, Abrdn Life Sciences Investors had 5 more articles in the media than SuRo Capital. MarketBeat recorded 5 mentions for Abrdn Life Sciences Investors and 0 mentions for SuRo Capital. Abrdn Life Sciences Investors' average media sentiment score of 1.57 beat SuRo Capital's score of 0.00 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the news media.
Summary
Abrdn Life Sciences Investors beats SuRo Capital on 8 of the 13 factors compared between the two stocks.
Get SuRo Capital News Delivered to You Automatically
Sign up to receive the latest news and ratings for SSSS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SSSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SuRo Capital Competitors List
Related Companies and Tools
